A novel Diclofenac-carrier for local treatment of osteoarthritis applying live-animal MRI

Elron-Gross, Inbar; Glucksam, Yifat; Biton, Inbal E.; Margalit, Rimona

doi:10.1016/j.jconrel.2008.12.005

Cited by 34 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourteen studies show incorporation of an NSAID [26][27][28][29][30][31][32][33][34][35][36][37][38][39] and two studies incorporated Celecoxib (Cxb) [40,41] in their carrier. Glucocorticoids were incorporated in six different studies [42][43][44][45][46][47] and HA in three [48][49][50].…”

Section: Nsaids Coxibs Glucocorticoids and Hyaluronanmentioning

confidence: 99%

“…In 2001, Trif et al reported a positive effect of human Lactoferrin encapsulated in liposomes in collagen-induced arthritis in mice [91]. Elron-Gross et al reported a reduction of inflammation in a monosodium iodoacetate (MIA) induced OA rat knee after a liposomal dexamethasone and diclofenac combination injection as compared to control assessed by MRI, in 2009 [32,92], and Dong et al found a combination of Cxb incorporated liposomes and HA to be more effective in pain control and cartilage protection than a single Cxb injection, Cxb liposome, and HA treatment alone [93]. Although liposomes are well established, and are effective and biocompatible, IA residence time is relatively short compared to other DDSs [18].…”

Section: Liposomesmentioning

confidence: 99%

See 1 more Smart Citation

Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

et al. 2014

View full text Add to dashboard Cite

Osteoarthritis (OA) is a big burden of disease worldwide and one of the most common causes of disability in the adult population. Currently applied therapies consist of physical therapy, oral medication, intra-articular injections, and surgical interventions, with the main goal being to reduce pain and improve function and quality of life. Intra-articular (IA) administration of drugs has potential benefits in OA treatment because it minimizes systemic bioavailability and side effects associated with oral administration of drugs without compromising the therapeutic effect in the joint. However, IA drug residence time is short and there is a clinical need for a vehicle that is able to provide a sustained release long enough for IA therapy to fulfill its promise. This review summarizes the use of different polymeric systems and the incorporated drugs for IA drug delivery in the osteoarthritic joint with a primary focus on clinical needs and opportunities.

show abstract

Section: Nsaids Coxibs Glucocorticoids and Hyaluronanmentioning

confidence: 99%

Section: Liposomesmentioning

confidence: 99%

Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Polymeric nanoparticles are colloidal structures below 1 μm and have been used to encapsulate lipophilic drugs to target organs and/or tissues, to avoid drug degradation, to improve its efficacy, and to circumvent its toxicity (Adair et al, 2010;Couvreur et al, 2002). Nanoencapsulation of drugs was observed to greatly prolong their pharmacological activity and decrease their toxicity (Alves et al, 2011;Bernardi et al, 2009;Elron-Gross et al, 2009;Grillo et al, 2010). In particular, the systemic administration of 15d-PGJ 2 -NC, when compared to unloaded 15d-PGJ 2, was found to improve the latency and the anti-inflammatory effect of the 15d-PGJ 2 at a much smaller dose (Alves et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception

et al. 2012

View full text Add to dashboard Cite

Aims: To verify whether the nanoencapsulation of 15d-PGJ 2 in poly(D,L-lactide-co-glycolide) (PLGA) nanocapsules (15d-PGJ 2 -NC) might potentialize its antinociceptive activity into rats' temporomandibular joint (TMJ). Main methods: Transmission electron microscopy (TEM) and atomic force microscopy (AFM) were used to evaluate the morphology and suspension of the PLGA nanocapsules. Rats were pretreated (15 min) with an intra-TMJ injection of unloaded 15d-PGJ 2 or 15d-PGJ 2 -NC at concentrations of 10, 100 or 1000 pg followed by an ipsilateral intra-TMJ injection of 1.5% formalin. The nociceptive behavioral response was observed during 45 min; animals were then sacrificed and the periarticular tissue was removed for IL-1β measurements. Key finding: TEM and AFM analyses showed that 15d-PGJ 2 -NC is spherical without any aggregates or adhesion confirming that this formulation is a good drug carrier system for 15d-PGJ 2 . Pretreatment with 15d-PGJ 2 -NC (100 and 1000 pg/TMJ), but not unloaded 15d-PGJ 2 , was found to significantly decrease the release of IL-1β cytokine and the animals' nociceptive behavioral response induced by intra-TMJ injection of formalin. Significance: The compound 15d-PGJ 2 -NC might be used as a potential antinociceptive and anti-inflammatory agent to treat temporomandibular disorders in clinical practice.

show abstract

“…Diclofenac was the test NSAID, and collagomers-novel vesicularshaped microparticles based on collagen-lipid conjugateswere the carriers. Collagomers were stable in simulated synovial fluid and showed high-efficiency drug encapsulation (85%) and slow drug release (τ 1/2 = 11 days) as well as high affinity to target cells (Kd = 2.6 nM collagen) [45].…”

Section: 2mentioning

confidence: 99%

Micro- and Nano-Carrier Mediated Intra-Articular Drug Delivery Systems for the Treatment of Osteoarthritis

Zhang

Huang

2012

Journal of Nanotechnology

View full text Add to dashboard Cite

The objective of this paper is to provide readers with current developments of intra-articular drug delivery systems. In recent years, although the search for a clinically successful ideal carrier is ongoing, sustained-release systems, such as polymeric micro-and nanoparticles, liposomes, and hydrogels, are being extensively studied for intra-articular drug delivery purposes. The advantages associated with long-acting preparations include a longer effect of the drug in the action site and a reduced risk of infection due to numerous injections consequently. This paper discusses the recent developments in the field of intra-articular sustained-release delivery systems for the treatment of osteoarthritis.

show abstract

A novel Diclofenac-carrier for local treatment of osteoarthritis applying live-animal MRI

Cited by 34 publications

References 25 publications

Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception

Micro- and Nano-Carrier Mediated Intra-Articular Drug Delivery Systems for the Treatment of Osteoarthritis

Contact Info

Product

Resources

About